Formulación, desarrollo y evaluación de comprimidos de liberación sostenida de flubiprofeno mediante un enfoque de calidad por diseño

Introduction: Flurbiprofen acts by blocking the cyclooxygenase (COX) enzymes in your body from carrying out their normal function. The study made flubiprofen tablets that last a long time by directly compressing them with carbopol, HPMC K100M, and HPMC K4M polymers. An anti-inflammatory non-steroid is flubiprofen. Method: The research formulates and develops sustained-release flubiprofen tablets by direct compression with carbopol, HPMC K100M, and HPMC K4M polymers. The highest flubiprofen concentration in ethanol, according to pre-formulation tests, was 215 nm. Results: The compressibility tablet was tested for thickness, diameter, medication content, and friability. Every exam was good. The compressibility index, bulk density, angle of repose, and tapped density showed good results for the tablet mix. In-vitro release tests were performed utilizing a USP device type II at 50 RPM, 0.1 N HCl in the dissolving media for two hours, and phosphate buffer pH 6.8 for six hours at 37 +0.5°C. A UV-visible spectrophotometer with a 215 nm setting assessed drug release at different periods. This formulation research indicated 99.25 % drug release from F2. Conclusions: One benefit of the sustained release dosage form is that it allows a medication to be administered gradually over an extended period in order to keep the blood level of concentration constant. This may improve patient compliance and increase drug output.